Ozempic Stomach Paralysis and Bowel Obstruction Lawsuits

Updated October 2026

About 4,000 lawsuits allege that GLP-1 drugs used for diabetes and weight loss can cause severe digestive injuries, including gastroparesis (stomach paralysis), ileus and intestinal obstruction, and that patients were not adequately warned.

Where the Litigation Stands

• Case: In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094, U.S. District Court for the Eastern District of Pennsylvania, before Judge Karen S. Marston.
• Size: about 4,000 cases were pending as of October 1, 2026.
• Recent activity: the court held expert hearings in September and October 2026. A ruling is expected before any trial dates are set.

Who May Qualify

• You took Ozempic, Wegovy, Rybelsus, Saxenda, Trulicity, Mounjaro or Zepbound
• You were diagnosed with gastroparesis, ileus or an intestinal obstruction, or were hospitalized for severe vomiting or blockage
• For gastroparesis claims, the court requires a gastric emptying study done at the time of diagnosis

What to Gather

• Pharmacy records for the GLP-1 drug
• Hospital and gastroenterology records
• Any gastric emptying study, endoscopy or imaging results

Frequently Asked Questions

I never had a gastric emptying study. Do I still have a claim?

For gastroparesis, the court requires one. Other injuries, such as a bowel obstruction confirmed by imaging, are handled differently. Tell us what testing you had.

Does it matter whether I took the drug for diabetes or weight loss?

No. Both are covered.

Is there a deadline?

Yes. Ask as soon as you can, because California deadlines can run from when you learned of the injury and its possible cause.